AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

AbbVie records a $3.5 billion impairment charge following the failure of emraclidine in Phase II schizophrenia trials.

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?

AbbVie had said it is evaluating other Cerevel-related drug development programs and will monitor the remaining intangible assets of about $3.6 billion. Sign up here. Singapore Telecommunications ...